However, it has been reported that SYK possesses both tumor promoter and suppressor roles in human breast carcinoma and that decreased expression is associated with a poor prognosis [80,81,82]; thus, SYK inhibition may work either synergistically or antagonistically with erlotinib. Here, SYK is linked to neoplasm.